Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Rating)’s share price was down 4.2% during trading on Tuesday . The stock traded as low as $24.75 and last traded at $24.95. Approximately 14,009 shares traded hands during trading, a decline of 99% from the average daily volume of 1,017,988 shares. The stock had previously closed at $26.05.
Several equities research analysts have recently commented on MRVI shares. Robert W. Baird cut their price target on Maravai LifeSciences from $48.00 to $40.00 in a research note on Friday, May 6th. Morgan Stanley cut their price target on Maravai LifeSciences from $59.00 to $54.00 and set an “overweight” rating for the company in a research note on Friday, February 25th.
The company has a debt-to-equity ratio of 0.80, a current ratio of 7.14 and a quick ratio of 6.55. The company has a 50 day moving average price of $32.71 and a 200 day moving average price of $34.74. The firm has a market cap of $6.51 billion, a PE ratio of 16.38 and a beta of 0.76.
Maravai LifeSciences (NASDAQ:MRVI – Get Rating) last announced its quarterly earnings data on Thursday, May 5th. The company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.43 by $0.11. The firm had revenue of $244.30 million for the quarter, compared to analyst estimates of $232.29 million. Maravai LifeSciences had a return on equity of 96.51% and a net margin of 25.25%. Maravai LifeSciences’s quarterly revenue was up 64.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.26 earnings per share. On average, equities analysts anticipate that Maravai LifeSciences Holdings, Inc. will post 1.85 earnings per share for the current fiscal year.
A number of institutional investors have recently bought and sold shares of the business. Select Equity Group L.P. grew its holdings in Maravai LifeSciences by 69.5% in the fourth quarter. Select Equity Group L.P. now owns 20,542,503 shares of the company’s stock valued at $860,731,000 after purchasing an additional 8,420,492 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Maravai LifeSciences by 12.0% in the first quarter. Massachusetts Financial Services Co. MA now owns 8,965,103 shares of the company’s stock valued at $316,198,000 after purchasing an additional 962,082 shares during the last quarter. BlackRock Inc. grew its holdings in Maravai LifeSciences by 30.7% in the fourth quarter. BlackRock Inc. now owns 6,053,047 shares of the company’s stock valued at $253,622,000 after purchasing an additional 1,420,288 shares during the last quarter. UBS Asset Management Americas Inc. grew its holdings in Maravai LifeSciences by 16.8% in the third quarter. UBS Asset Management Americas Inc. now owns 4,133,186 shares of the company’s stock valued at $202,857,000 after purchasing an additional 594,447 shares during the last quarter. Finally, Champlain Investment Partners LLC boosted its stake in shares of Maravai LifeSciences by 0.8% during the first quarter. Champlain Investment Partners LLC now owns 3,582,530 shares of the company’s stock valued at $126,356,000 after acquiring an additional 28,405 shares during the last quarter. 50.18% of the stock is currently owned by institutional investors.
About Maravai LifeSciences (NASDAQ:MRVI)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Read More
Receive News & Ratings for Maravai LifeSciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Maravai LifeSciences and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
